Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.11% | -20.78% | -24.53% | -10.37% | -33.29% |
| Total Depreciation and Amortization | 83.81% | 258.09% | -- | -- | -- |
| Total Amortization of Deferred Charges | 18.23% | 28.79% | 51.39% | 46.39% | 38.25% |
| Total Other Non-Cash Items | 20.26% | 21.45% | -10.44% | -43.95% | -16.20% |
| Change in Net Operating Assets | 9.93% | 12.39% | 10.40% | 9.91% | 6.62% |
| Cash from Operations | 23.06% | 23.70% | -3.28% | -10.08% | -14.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | 99.70% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -53.73% | -75.50% | -20.79% | 42.51% | 62.25% |
| Cash from Investing | -44.74% | -66.87% | -24.35% | 39.73% | 59.91% |
| Total Debt Issued | -98.45% | -- | 119.51% | 119.51% | 77.32% |
| Total Debt Repaid | 81.10% | -- | -- | -- | -550.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 78.19% | 72.02% | 39.40% | -434.46% | -478.76% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -8.29% | -6.04% | -2.48% | -0.47% | -1.46% |
| Other Financing Activities | 5.39% | -1.99% | 1.38% | -6.12% | -3.40% |
| Cash from Financing | -34.94% | 86.09% | -40.52% | -428.39% | -395.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,728.66% | 115.90% | -304.86% | -168.65% | -181.65% |